Glaxosmithkline Pharmaceuticals Ltd vs Sai Life Sciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Glaxosmithkline Pharmaceuticals Ltd is ₹ 2350 as of 04 May 10:50 . The P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 yearsThe P/E Ratio of Sai Life Sciences Ltd changed from 93.4 on March 2025 to 93.4 on March 2025 . This represents a CAGR of 0.00% over 1 years The Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 yearsThe Market Cap of Sai Life Sciences Ltd changed from ₹ 15883 crore on March 2025 to ₹ 15883 crore on March 2025 . This represents a CAGR of 0.00% over 1 years The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 1091 crore as compare to the Sep '25 revenue of ₹ 1016 crore. This represent the growth of 7.4% The revenue of Sai Life Sciences Ltd for the Dec '25 is ₹ 564.84 crore as compare to the Sep '25 revenue of ₹ 552.8 crore. This represent the growth of 2.18% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Dec '25 is ₹ 421.44 crore as compare to the Sep '25 ebitda of ₹ 371.94 crore. This represent the growth of 13.31% The ebitda of Sai Life Sciences Ltd for the Dec '25 is ₹ 187.94 crore as compare to the Sep '25 ebitda of ₹ 161.15 crore. This represent the growth of 16.62% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 295.62 crore over 7 quarters. This represents a CAGR of 31.80% The net profit of Sai Life Sciences Ltd changed from ₹ -13.5 crore to ₹ 100.38 crore over 7 quarters. This represents a CAGR of NaN% The Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 yearsThe Dividend Payout of Sai Life Sciences Ltd changed from 443.82 % on March 2022 to 0 % on March 2025 . This represents a CAGR of -100.00% over 4 years .

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

About Sai Life Sciences Ltd

Sai Life Sciences Limited was originally incorporated as Sai Dru Syn Laboratories Limited' as a Public Limited Company, dated January 25, 1999, issued by the Registrar of Companies, Andhra Pradesh at Hyderabad.
The Company received the Certificate of Commencement of Business from Registrar of Companies, Andhra Pradesh on February 17, 1999.
Subsequently, the Company name was changed from Sai Dru Syn Laboratories Limited' to Sai Life Sciences Limited' dated December 16, 2003. Thereafter, the name of the Company was changed from Sai Life Sciences Limited' to Sai Advantium Pharma Limited' dated August 30, 2006 issued by the Registrar of Companies, Andhra Pradesh.
Subsequently, the Company name was changed from Sai Advantium Pharma Limited' to Sai Life Sciences Limited' and a fresh Certificate of Incorporation dated May 28, 2012 was issued by the Registrar of Companies, Andhra Pradesh at Hyderabad.

FAQs for the comparison of Glaxosmithkline Pharmaceuticals Ltd and Sai Life Sciences Ltd

Which company has a larger market capitalization, Glaxosmithkline Pharmaceuticals Ltd or Sai Life Sciences Ltd?

Market cap of Glaxosmithkline Pharmaceuticals Ltd is 39,566 Cr while Market cap of Sai Life Sciences Ltd is 22,668 Cr

What are the key factors driving the stock performance of Glaxosmithkline Pharmaceuticals Ltd and Sai Life Sciences Ltd?

The stock performance of Glaxosmithkline Pharmaceuticals Ltd and Sai Life Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Glaxosmithkline Pharmaceuticals Ltd and Sai Life Sciences Ltd?

As of May 4, 2026, the Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2335.6. On the other hand, Sai Life Sciences Ltd stock price is INR ₹1070.4.

How do dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Sai Life Sciences Ltd compare?

To compare the dividend payouts of Glaxosmithkline Pharmaceuticals Ltd and Sai Life Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.